Plain-English translation of NCT06512194 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Depression research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is investigating — a naturally occurring psychedelic compound — as a potential treatment for depression. You would receive a single 25 mg dose of this medication in a carefully controlled, therapeutic setting with trained facilitators present. The study is designed to see whether different types of support after the dose — including a special brain stimulation technique or reflection sessions — might help improve the antidepressant effects of the treatment.
Traditional antidepressants don't work for everyone, and some people need new approaches. Early research suggests that the medication, when given with proper psychological support, may have rapid and lasting effects on depression, and this trial aims to figure out the best way to optimize those benefits.
You likely qualify if…
You likely don't qualify if…
You would attend several preparation sessions before receiving a single dose of the medication in a controlled clinical setting, with two trained facilitators present throughout. After the dosing day, you'll be randomly assigned to one of three groups: some participants will receive twice-daily sessions of a non-invasive brain stimulation technique paired with music and reflection prompts for 7 days, others will receive a sham (fake) version of that technique, and a third group will receive standard supportive sessions only. Throughout the study, you'll complete regular check-ins and questionnaires to track changes in your depression, anxiety, mood, and overall quality of life.
AI-generated summary from trial data · Jul 5, 2026 · Not medical advice
United States